Department of Medical Research, Holstebro Hospital, Holstebro, Denmark.
Am J Hypertens. 2012 Nov;25(11):1215-22. doi: 10.1038/ajh.2012.111. Epub 2012 Aug 2.
Low 25-hydroxy-vitamin D (25(OH)D) levels are inversely related to blood pressure (BP) and have been associated with incident hypertension. In people living at northern latitudes diminished cholecalciferol synthesis in the winter increases the risk of vitamin D deficiency. We wanted to test the hypothesis that daily cholecalciferol supplementation in the winter lowers BP in patients with hypertension.
We investigated the effect of 75 µg (3,000 IU) cholecalciferol per day in a randomized, placebo-controlled, double-blind study in 130 hypertensive patients residing in Denmark (56º N). Ambulatory BP (24-h BP) and arterial stiffness were measured before and after 20 weeks of treatment, that took place between October and March.
A total of 112 patients (mean age 61 ± 10) with a baseline p-25(OH)D of 23 ± 10 ng/ml completed the study. Compared with placebo, a nonsignificant 3/1 mm Hg (P = 0.26/0.18) reduction was found in 24-h BP. In patients with vitamin D insufficiency (<32 ng/ml) at baseline (n = 92), 24-h BP decreased by 4/3 mm Hg (P = 0.05/0.01). Central BP (CBP) estimated by applanation tonometry and calibrated with a standardized office BP was reduced by 7/2 mm Hg (P = 0.007/0.15) vs. placebo. No differences in carotid-femoral pulse wave velocity (PWV) or central augmentation index (AIx) were found between treatment arms.
Cholecalciferol supplementation, by a dose that effectively increased vitamin D levels, did not reduce 24-h BP, although central systolic BP decreased significantly. In a post-hoc subgroup analysis of 92 subjects with baseline p-25(OH)D levels <32 ng/ml, significant decreases in 24-h systolic and diastolic BP occurred during cholecalciferol supplementation.
低水平的 25-羟维生素 D(25(OH)D)与血压(BP)呈负相关,并且与高血压的发生有关。在生活在高纬度地区的人群中,冬季胆钙化醇合成减少会增加维生素 D 缺乏的风险。我们想验证这样一个假设,即在冬季每天补充胆钙化醇可以降低高血压患者的血压。
我们在丹麦(北纬 56°)进行了一项随机、安慰剂对照、双盲研究,共纳入 130 名高血压患者,每天给予 75μg(3000IU)胆钙化醇,治疗时间为 20 周,从 10 月到 3 月。在治疗前后,我们使用动态血压监测(24 小时血压)和动脉僵硬度来测量血压和动脉僵硬度。
共有 112 名患者(平均年龄 61±10 岁)完成了研究,他们的基线 p-25(OH)D 为 23±10ng/ml。与安慰剂相比,24 小时 BP 仅降低了 3/1mmHg(P=0.26/0.18),但无统计学意义。在基线时维生素 D 不足(<32ng/ml)的 92 名患者中,24 小时 BP 降低了 4/3mmHg(P=0.05/0.01)。应用平板压力测量法估计的中心血压(CBP)与标准诊室血压校准后,降低了 7/2mmHg(P=0.007/0.15)。颈动脉-股动脉脉搏波速度(PWV)或中心增强指数(AIx)在治疗组之间无差异。
补充胆钙化醇的剂量有效提高了维生素 D 水平,但并未降低 24 小时 BP,尽管中心收缩压显著降低。在基线 p-25(OH)D 水平<32ng/ml 的 92 名患者的亚组分析中,24 小时收缩压和舒张压在胆钙化醇补充期间显著降低。